Feldan Therapeutics nabs $12.5 mln in GC-led Series A round

Québec City-based biotechnology company Feldan Therapeutics has raised $12.5 million in a Series A financing. The round was led by GC, the parent of South Korean protein therapeutics maker GC Pharma. It was joined by Stonebridge Ventures as well as Anges Québec and Anges Québec Capital, both existing investors, and others. Led by CEO Francois-Thomas Michaud, who helped launch the company in 2007, Feldan is developing a pipeline of therapeutic applications based on the Feldan Shuttle, its peptide intracellular delivery technology. The funds raised will support pre-clinical work that will enable the transfer of Feldan's technology to clinical trials.

CanadaNorth AmericaBriefs